retatrutide korea approval Company linked to raid on illicit weight-loss drug facility still selling unlicensed drugs | Consumer affairs Newsflash: if you are buying

This will lead to many people losing access to the medication and back to square one: weight loss through lifestyle change alone

Common adverse events that occurred at the same rate or greater for NOVOLOG-treated patients than in comparator-treated patients during clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus (other than hypoglycemia) are listed in Table 1 and Table 2, respectively

Data availability No datasets were generated or analyzed during the current study

Their neglect reflects historical limitations rather than biological inadequacy

In an additional, 30-week placebo-controlled, study of patients with type 2 diabetes inadequately controlled with metformin comparing the maintenance of sitagliptin 100 mg versus withdrawal of sitagliptin when initiating basal insulin therapy, the event rate and incidence of documented symptomatic hypoglycemia (blood glucose measurement 70 mg/dL) did not differ between the sitagliptin and placebo groups

Long-term use may require periodic reevaluation to assess benefits, side effects, and any need for dosage adjustments